EGFR and non-small cell lung carcinoma: A recent plasma‐based study also reported 4 out of 24 NSCLC patients had EGFR‐sensitizing mutations detected in plasma at T0 but absent when the patients progressed, which agreed with our findings (Pecuchet et al, 2016).